Entrada Therapeutics (NASDAQ:TRDA) Stock Price Target Lowered at Guggenheim

Entrada Therapeutics logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • Guggenheim cut its price target on Entrada Therapeutics from $17 to $13 but maintained a Buy rating; the new target implied 162.1% upside from the prior close.
  • Analyst views are mixed: the stock has a consensus Hold rating and an average price target of $16.75, with four Buy, two Hold, and one Sell ratings.
  • Entrada reported a quarterly loss of $0.94 per share, narrower than expected, but revenue of $0.91 million fell short of the $2.30 million consensus estimate. Shares opened at $4.96, near their 52-week low of $4.11.
  • MarketBeat previews the top five stocks to own by December 1st.

Entrada Therapeutics (NASDAQ:TRDA - Get Free Report) had its price target decreased by research analysts at Guggenheim from $17.00 to $13.00 in a research report issued on Wednesday, Benzinga reports. The brokerage presently has a "buy" rating on the stock. Guggenheim's price objective points to a potential upside of 162.10% from the stock's previous close.

Several other equities research analysts also recently weighed in on the company. UBS Group restated a "neutral" rating on shares of Entrada Therapeutics in a report on Monday, October 19th. HC Wainwright reiterated a "neutral" rating on shares of Entrada Therapeutics in a research note on Monday, October 19th. Roth Capital reissued a "buy" rating and set a $11.00 price objective on shares of Entrada Therapeutics in a research report on Wednesday, August 12th. Wall Street Zen upgraded shares of Entrada Therapeutics from a "sell" rating to a "hold" rating in a research note on Monday, November 9th. Finally, Weiss Ratings upgraded shares of Entrada Therapeutics from a "sell (e+)" rating to a "sell (d-)" rating in a research note on Wednesday, November 4th. Four investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the stock presently has an average rating of "Hold" and a consensus target price of $16.75.

Read Our Latest Stock Report on Entrada Therapeutics

Entrada Therapeutics Stock Performance

NASDAQ:TRDA opened at $4.96 on Wednesday. Entrada Therapeutics has a 52 week low of $4.11 and a 52 week high of $16.45. The company has a fifty day simple moving average of $5.50 and a two-hundred day simple moving average of $8.36.

Entrada Therapeutics (NASDAQ:TRDA - Get Free Report) last announced its quarterly earnings data on Thursday, November 5th. The company reported ($0.94) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.01) by $0.07. The business had revenue of $0.91 million for the quarter, compared to analysts' expectations of $2.30 million. Entrada Therapeutics had a negative return on equity of 64.00% and a negative net margin of 4,057.98%. Equities analysts expect that Entrada Therapeutics will post -4.12 EPS for the current year.

Insider Activity

In related news, major shareholder Bioventures 2014 L.P. Mpm sold 26,522 shares of the business's stock in a transaction that occurred on Tuesday, August 25th. The stock was sold at an average price of $7.54, for a total transaction of $199,975.88. Following the completion of the sale, the insider owned 4,332,917 shares in the company, valued at $32,670,194.18. The trade was a 0.61% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, major shareholder Bioventures 2018 L.P. Mpm sold 192,500 shares of the business's stock in a transaction that occurred on Tuesday, September 8th. The stock was sold at an average price of $7.41, for a total value of $1,426,425.00. Following the sale, the insider owned 3,913,952 shares of the company's stock, valued at approximately $29,002,384.32. The trade was a 4.69% decrease in their position. The SEC filing for this sale provides additional information. Over the last ninety days, insiders have sold 495,947 shares of company stock valued at $3,600,470. Insiders own 9.49% of the company's stock.

Hedge Funds Weigh In On Entrada Therapeutics

Several hedge funds have recently added to or reduced their stakes in the stock. 5AM Venture Management LLC acquired a new position in Entrada Therapeutics in the second quarter valued at $29,854,949. BlackRock Inc. acquired a new stake in shares of Entrada Therapeutics during the second quarter worth about $19,013,000. Dimensional Fund Advisors LP increased its position in shares of Entrada Therapeutics by 18.7% during the first quarter. Dimensional Fund Advisors LP now owns 324,471 shares of the company's stock worth $4,092,000 after purchasing an additional 51,093 shares in the last quarter. Nantahala Capital Management LLC acquired a new stake in shares of Entrada Therapeutics during the second quarter worth about $2,212,232. Finally, Goldman Sachs Group Inc. lifted its holdings in shares of Entrada Therapeutics by 68.1% in the 3rd quarter. Goldman Sachs Group Inc. now owns 298,172 shares of the company's stock valued at $1,893,000 after purchasing an additional 120,829 shares during the last quarter. 86.39% of the stock is currently owned by hedge funds and other institutional investors.

Entrada Therapeutics Company Profile

(Get Free Report)

Entrada Therapeutics is a biotechnology company focused on developing medicines that deliver therapeutic molecules into cells. Founded in 2016 and based in Boston, Massachusetts, the company developed its Endosomal Escape Vehicle (EEV) platform to help move drug cargo across cellular membranes and reach intracellular targets. The company's research centers on its EEV-based oligonucleotide medicines, including programs designed to address genetic causes of neuromuscular diseases. Its development work includes candidates intended to alter RNA processing for Duchenne muscular dystrophy, with programs targeting different genetic subgroups of the disease.

Read More

Analyst Recommendations for Entrada Therapeutics (NASDAQ:TRDA)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Entrada Therapeutics Right Now?

Before you consider Entrada Therapeutics, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Entrada Therapeutics wasn't on the list.

While Entrada Therapeutics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

7 Blue-Chip Stocks to Add To Your Forever Portfolio Cover

A strong long-term portfolio starts with companies that can survive recessions, inflation, changing consumer habits, and shifting market leadership.

This report names seven blue-chip stocks across technology, retail, consumer staples, healthcare, networking, sporting goods, and utilities that offer investors a mix of stability, income, growth, and staying power.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines